As we previously reported, on June 3, 2022, Genentech filed a complaint against Tanvex in the U.S. District Court for the Southern District of Florida, alleging infringement of three patents under the BPCIA based on Tanvex’s submission of an aBLA for TX05, a proposed biosimilar of HERCEPTIN (trastuzumab). The three asserted patents are generally
More Posts
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free, High-Concentration Adalimumab Biosimilar
PTAB Institutes Sixth IPR on a Tocilizumab Patent Challenged by Fresenius
New BPCIA Complaint: Genentech Files Suit Against Tanvex Regarding its Proposed Herceptin Biosimilar
Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA (pegfilgrastim-pbbk)
Trial Scheduled for April 2024 in BMS Patent Case Against AstraZeneca Regarding Anti-PDL1 Antibodies
Pfizer Files Lawsuit in Australia to Halt Sales of BRENZYS (etanercept)
Amgen Announces Positive Results for Phase 3 Study of Ustekinumab Biosimilar
PTAB Institutes Another IPR on a Tocilizumab Patent Challenged by Fresenius
PTAB Institutes Two More IPRs on Tocilizumab Patents Challenged by Fresenius
Subscribe: Subscribe via RSS
Blogs
Firm/Org